Community-acquired pneumonia: biomarkers of inflammation and Omega-3 polyunsaturated fatty acids

Bibliography:
1. Sinopalnikov Al, Kozlov RS. Community-acquired respiratory tract infections: guidelines for clinicians. SPb.: Premer MT, Nash Gorod, 2007; 352 p.; 2. Yakovlev SV. Community-acquired pneumonia in the elderly: particular etiology, clinical course and antibiotic therapy Russian Medical Journal 1999; 7 (16(98): 763-768; 3. Chuchalin AG, Sinopalnikov Al, Kozlov Rl, et al. Community-Acquired Pneumonia: Guidelines on diagnosis, Treatment and Prophylaxis. Guidelines for Clinicians (approved by the Ministry of Health of Russian Federation). Clinical Microbiology and Antimicrobial Chemotherapy 2010; 12(3): 186-224; 4. Novikov YK. Diagnosis and treatment of community-acquired pneumonia. Russian Medical Journal 2001; 3(1-2)6: 11-16; 5. Strachunskiy LS. Antibiotic therapy of community-acquired pneumonia in an outpatient setting. Consilium medicum 2002; 4(4): 180.; 6. Houck РМ, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-aquired pneumonia. Arch Intern Med 2004; 164(6): 637-44; 7. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275(2): 134-41; 8. Lim WS, van der Erden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58(5): 377-82; 9. Yandiola PP, CapelasteguiA, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009; 135(6): 1572-9; 10. Dvoretskiy LI, Aleksandrova MA. Clinical guidelines for the diagnosis and treatment of community-acquired pneumonia. Russian Medical Journal 2010; 9: 522-529; 11. Torabinejad М, Cotti Е, Lessard G. Leukotrienes: their possible role in pulmal and periapical diseases. Endod dent Traumatol 1991;7:233-241; 12. Bisgard H, Pedersen M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy 1987; 17(2): 95-103; 13. Karaulov AV, Silvestrov VP, et al. The role of eicosanoids: prostaglandins, prostacyclin, thromboxane and leukotrienes in the pathogenesis of asthma and other lung diseases. Therapeutic Archive 1986; 3: 123-130; 14. Masuev КА Eicosanoids and asthma. Pulmonology 1993; 1: 78-81; 15. Pasechnikov VD. Lipooxygenase synthesis of arachidonic acid metabolites and their role in the pathogenesis of inflammation of the gastric mucosa. Clinical Medicine 1991; 9: 69-72; 16. Kolosov VP, Kochegarova EYu, Naryshkina SV. Community-acquired pneumonia (clinical course, predicting outcomes). Blagoveshchensk, 2012; 124 p.; 17. Velkov VV Procalcitonin and C-reactive protein in modern laboratory diagnostics. Part 1. Clinical and laboratory consilium. Scientific-Practical Journal 2008; 6(25): 46-52; 18. Velkov VV. Procalcitonin and C-reactive protein in modern laboratory diagnostics. Part 2. Clinical and laboratory consilium. Scientific-Practical Journal 2009; 1 (26): 34-48; 19. Titov VN. C-reactive protein: physico-chemical properties, structure and specific properties. Clinical Laboratory Diagnostics 2004; 8: 3-10; 20. Geltser Bl, Kukol LV. Clinical estimation the effectiveness of prognostic scales in patients with community-acquired pneumonia. Clinical Medicine 2003; 11: 62-66; 21. Korppi М, Kroger L. C-reactive protein in viral and bacterial respiratory infection. Scand J Infect Dis 1993; 25 (2): 207-213; 22. Paltsev MA, Ivanov AA, Severin SV. Intercellular interactions. 2nd edition, revised and enlarged. Moscow: Meditsina, 2003; 288 p.; 23. Volozhin Al, Poryadkin GV, et al. Pathophysiology Moscow: Akademiya, 2006; 1: 272 p.; 24. Baymakanova GE, Zubairova PA, Avdeev SN, et al. Features of the clinical picture and community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Pulmonology 2009; 2: 33-41; 25. Shevchenko OP High-sensitivity analysis of C-reactive protein and its application in cardiology. Laboratory medicine 2003; 6: 35-41; 26. Meisner М., Tschaikowsky К., Palmaers Т., et al. Т. Comparison of procalcitonin(PCT) and C-reactive protein(CRP) plasma concentration at different SOFA scores during the course of sepsis and MDOS. Crit Care 1999; 3(1): 45-50; 27. Zubairova PA. Features of the clinical picture, prognosis and the role of biomarkers of inflammation in patients with pneumonia, chronic obstructive pulmonary disease: PhD abstract. Moscow, 2010; 114 p.; 28. Wicher J, Bienvenu J, Monneret G. Procalcitonin as an acture phase marker. Ann Clin Biochem 2001; 38(Pt5): 438-493; 29. Aouifi A, Piriou V, Bastien O, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000; 28 (9): 3171-6; 30. Christ-Crain M, Muller B. Procalcitoninum in bacterial infections: hype, hope, more or less? Swiss Med Wkly 2005; 135 (31-32): 451-460; 31. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in icritically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34(7): 1996-2003; 32. Joram N, Boscher C, Denizot S, et al. Umbilical cord blood procalcitonin C-reactive protein concentration as markers for early diagnosis of very early onset neonatal infection. Arch Dis Child Fetal Neonatal Ed 2006; 91(1): 65-66; 33. Chiesa C, Panero A, Rossi N. Reliability of procalcitonin concentration for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis1998; 26(3): 664-672; 34. Dandola P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab1994;79(6): 1605-8; 35. Simbirtsev AS. Cytokines: classification and biological functions. Cytokines and Inflammation 2004; 3(2): 16-21; 36. Brunkhorst FM, Wegscheider К, Forycky ZE, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000; 26(2): 148-52; 37. Tarasova IV «Kapellmeister» intercellular interactions -cytokines. Allergology and immunology in pediatrics 2011; 1(24): 36-40; 38. Kostyushko AV, Markelova EV. Cytokine profile enterobacterial pneumonia in the experiment. Patologicheskaya fiziologiya i eksperimental'naya meditsina 2010; 4: 27-31; 39. Simbirtsev AS. Cytokines: classification and biological functions. Cytokines and Inflammation 2004; 3(2): 9-14; 40. RydkovskayaAV, Simbirtsev AS. Functional polymorphism of TNF-a and pathology. Cytokines and Inflammation 2007; 4(3): 4-10; 41. Harris МС, Costarino AT Jr, Sullivan JS, et al. Cytokine elevations in critically ill infants with sepsis. Am J Respir J Pediatr. 1994; 1224(1): 105-11; 42. Vertkin AL, Prokhorovich EA, Namazova LS, et al. Optimization of the empirical treatment of community-acquired pneumonia in patients with elderly. Russian Medical Journal 2002; 10(16): 708-812; 43. Mehr S, Doyle LW. Cytokines as markers of bacterial sepsis in newborn in-fants: a review. Pediatr Infect Dis J 2007; 19(9): 879-887; 44. Menender R, Martinez R, Reyes S Biomarkers improve mortality pre-diction diagnostic scales in community-acquired pneumonia. Thorax. 2009; 64 (7): 587-591; 45. Velkov VV. Presepsin - new highly effective biomarker of sepsis. Clinical and laboratory consilium 2012; 2(42): 56-62; 46. Popov DA, Plyushch MG, Yarustovskiy MB, et al. Monitoring the level of SCD14-ST (presepsin) in perioperative period of cardiac surgery patients. Anesthesiology and Reanimatology 2013; 3: 30-35; 47. Shozushima Т, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011; 17(6): 764-769; 48. Endo S, Suzuki Y, Takahashi G, Shozushima T, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. 2012; 18(6): 891-7; 49. State Standard. The standard of care for patients with pneumonia caused by Streptococcus Pneumoniae, pneumonia caused by Hemophilus influenzae (Pfeiffer-stick Afanasyev) bacterial pneumonia not elsewhere classified; pneumonia caused by other infectious agents, unclassified pneumonia; pneumonia without specifying pathogen; lung abscess with pneumonia (with specialized assistance). Moscow, 2007; 50. Azhgikhin IS. Prostaglandins - a new class of biologically active substances. In: Prostaglandins. Moscow: Medicine, 1978; p. 245-260; 51. Denisenko РР, Ter-Karapetyan VA. The role of unsaturated fatty acids in inflammation. In: Proceedings of Congress USA 1995; p. 59; 52. Denisenko РР, Isaeva SR, Denisenko NP, et al. Therapeutic and prophylactic use of essential unsaturated fatty acids (review). Clinical Pharmacology and Therapeutics 1997; 9: 47-52; 53. Burbello AT Omega-3 polyunsaturated fatty acids. In: Pharmacology: clinical application. St. Petersburg, 2005; p. 304; 54. Komarov Fl, Serebryanskaya MV. Clinical and immunological aspects of the different variants of the peptic ulcer. Therapeutic Archive 1990; 2(62): 38-43; 55. Burbello AT, Shabrov AV, Serebryakova VI, et al. Immunocorrecting effects of antioxidants and polyunsaturated fatty acids in certain diseases of the internal organs. International Journal Immunorehabilitation 2000; 2(2): 46; 56. Azhgikhin IS, Ter-Karapetyan VA, Gandel VG, et al. Docosahexaenoic and eicosapentaenoic acid: new pharmaceutical and medical aspects. Farmatsiya 1987; 36(2):80-89; 57. Burbello AT, Frelikh МР, Shabrov AV, et al. Polyunsaturated fatty acids as a means of prevention of acute asthma. Vestnik of the St. Petersburg State Medical Academy named after I.I. Mechnikov 2000; 1: 43-46; 58. Burbello AT, Frelikh МР, Serebryakova VI, etal. Changing the state of the antioxidant status of the immune system and some patients influenced omega-3 polyunsaturated fatty acids and antioxidants. In: Proceedings of the VII Russian National Congress «Chelovek i lekarstvo». Moscow, 2000; p. 393-394; 59. Hurst S, Zainal Z, Caterson В, et al. Dietary fatty acids and arthritis. Prostaglandins Leucot Essent Fatty Acids 2010; 82(4-6): 315-8; 60. Gaykovaya LB, Kukharchik GA, Bogdanova VG, et al. Laboratory markers in the evaluation of anti-inflammatory effects of omega-3 polyunsaturated fatty acids. Cytokines and Inflammation 2011; 1.